Dr. Lawrence Eichenfield discusses a better understanding of disease pathogenesis, available therapies and proactive treatment approach improves the outlook for managing atopic dermatitis.
The news is good for today’s atopic dermatitis patients and the dermatologists who treat them, according to Lawrence Eichenfield, M.D., who co-directed the Atopic Dermatitis panel and spoke on topicals for atopic dermatitis Saturday, March 2, at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
“We are amidst a revolution in atopic dermatitis - in our understanding of disease pathogenesis and mediators, the disease impact on individuals and families and associated comorbidities and in the therapies we have available to manage it,” says Dr. Eichenfield, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and vice chair of dermatology and professor of dermatology and pediatrics at UC San Diego School of Medicine. “In the therapeutic arena, while we are thrilled with the introduction of systemic therapies, including biologic agents and small molecules such as the Janus kinase (JAK) inhibitors, we recognize that most atopic dermatitis can be well managed with topical agents.”
Optimal atopic dermatitis management is evolving as dermatologists emphasize effective control of dermatitis and itch - not just during flares, but across timepoints to minimize eczematous rashes, itch, sleep disturbance and secondary complications, according to Dr. Eichenfield.
Among the key takeaways from Dr. Eichenfield’s AAD talk:
Atopic dermatitis management is moving toward the approach taken with asthma, moving away from just reacting to flares to longer term treatment of the skin proactively to minimize active disease and symptoms, Dr. Eichenfield says.
Dr. Eichenfield has consulting and/or research ties to Allergan, Anacor Pharmaceuticals, Cutanea Life Sciences, Dr. Reddy, DS Laboratories, Galderma Laboratories, Genentech, Kimberly Clark, LEO Pharma, Lilly, Medimetriks Pharmaceuticals, Novan, Otsuka Pharmaceutical Co., Pfizer, Tioga Pharmaceuticals, TopMD, Ralexar Therapeutics, Sanofi-Regeneron, Valeant Pharmaceuticals International and Valeant Pharmaceuticals North America.